<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00397683</url>
  </required_header>
  <id_info>
    <org_study_id>0822-011</org_study_id>
    <secondary_id>2006_517</secondary_id>
    <nct_id>NCT00397683</nct_id>
  </id_info>
  <brief_title>A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011)</brief_title>
  <official_title>Proprietary Information - Exploratory (Non-Confirmatory) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test MK0822 on disease activity in patients with
      osteoarthritis in the knee. Disease modifying activity of MK0822 will be assessed by
      measurements of knee cartilage using Magnetic Resonance Imaging (MRI) of the knee.

      This is an early phase trial and some specific protocol information is proprietary and not
      publicly available at this time. (Full information is available to trial participants).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proprietary Information - Exploratory (Non-Confirmatory) Trial</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proprietary Information - Exploratory (Non-Confirmatory) Trial</measure>
  </secondary_outcome>
  <enrollment type="Actual">2</enrollment>
  <condition>Osteoarthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0822</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with symptomatic knee osteoarthritis for at least 6 months based on clinical
             and radiographic criteria

          -  Patients should be in general good health and must have a certain level of knee pain
             or be taking pain medicines on most days

          -  Specific radiographic (X-ray) and MRI features must also be satisfied

        Exclusion Criteria:

          -  Non-osteoarthritic causes of knee pain

          -  Ineligibility to undergo MRI of the knee due to patient tolerability or safety reasons

          -  Previous septic arthritis, tibial osteotomy or knee replacement in both knees

          -  Acute injury of knee ligaments or meniscus in past 2 years

          -  Knee arthroscopy in past 12 months

          -  Anticipated arthroscopy or surgery in next 18 months

          -  Use of intra-articular injections of hyaluronan (e.g. Hyalgan (TM), Synvisc (TM),
             Orthovisc (TM)) in past 6 months, or injections of glucocorticoids (e.g. Kenalog (TM),
             Aristospan (TM), Depo-Medrol (TM)) in past 3 months or anticipated knee injections
             during the study

          -  Glucosamine or chondroitin sulfate are allowable if they are at a stable dose for past
             3 months and will continue at that dose during the study

          -  Other exclusion criteria apply-Please ask the study doctor for details
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Call for Information</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Call for Information</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Call for Information</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Call for Information</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Call for Information</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Call for Information</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Call for Information</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143-0000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Call for Information</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Call for Information</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Call for Information</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Call for Information</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <zip>19401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Call for Information</name>
      <address>
        <city>Perkasie</city>
        <state>Pennsylvania</state>
        <zip>18944</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme (I.A.) Corp.</name>
      <address>
        <city>Santiago</city>
        <zip>6761641</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frosst Laboratories Inc.</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme De Mexico, S.A. De C.V.</name>
      <address>
        <city>Mexico</city>
        <state>D.f.</state>
        <zip>1090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MSD Polska Sp. z o.o. Dzial Medyczny</name>
      <address>
        <city>Warszawa</city>
        <zip>00-867</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2006</study_first_submitted>
  <study_first_submitted_qc>November 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2006</study_first_posted>
  <last_update_submitted>October 30, 2015</last_update_submitted>
  <last_update_submitted_qc>October 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

